Fig. 4

Blockade of AhR signals reverses EGFR TKIs resistance in lung cancer mice model. A, the tumor volume of A549 bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. B, the survival time of A549 bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. C, the tumor volume of Lewis bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. D, the survival time of Lewis bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. E, the tumor volume of A549 bearing mice treated with PBS, Gef, DMF, and Gef combined with DMF. F, the survival of A549 bearing mice treated with PBS, Gef, DMF, and Gef combined with DMF. G, the tumor volume of A549 (Kyn persistent treatment) bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. H, the survival time of A549 (Kyn persistent treatment) bearing mice treated with PBS, Erl, DMF, and Erl combined with DMF. * indicates P < 0.05. ** indicates P < 0.01. n.s. indicates no statistical significance